IL1B and neoplasm: To date, data from this current study and our previous studies [2,13] suggest that inhibiting IL-1 signalling is extremely effaceable against bone metastasis, inhibiting metastatic outgrowth and slowing the development of tumours in the bone; however, the same treatments appear to have the potential to increase metastatic outgrowth of tumour cells disseminated in lungs.